• Medical Science BMedSc 3
• Clinical Oncology MSc/Postgraduate Diploma

Professor James is Professor of Clinical Oncology at the University of Birmingham and Consultant in Clinical Oncology at the Queen Elizabeth Hospital specialising in urological oncology. He qualified in 1983 from St Bartholomew’s Hospital with the principal class prize in internal medicine. After general medical training in London and Brussels, oncology training was undertaken at Hammersmith, the Royal Marsden, St Mary’s and St Bartholomew’s Hospitals and the Cancer Institute, Tokyo. He has been based in Birmingham since 1994.

Current research is focused on clinical trials in urological tumours and information provision over the Internet. In 1994 he co-founded the leading patient website CancerHelp UK (www.cancerhelp.org.uk). Trials of the Birmingham-developed CTL102 adenovirus in prostate cancer have been successfully completed and a follow-on trial funded by the MRC is in preparation. In the urological clinical trials field, he is currently chief investigator on 2 large trials in prostate cancer STAMPEDE (www.stampedetrial.org) and TRAPEZE.

He is also chief investigator on the recently closed chemoradiotherapy trial BC2001 which is the largest randomised trial of radiotherapy in bladder cancer. Previously completed work includes being UK Chief Investigator for the pivotal TAX327 study, which lead to the licensing of Docetaxel in prostate cancer.

He has recently published a book on oncology entitled: Cancer, A Very Short Introduction.

• R&D Director (Cancer Research) University Hospitals Birmingham NHS FT
• Management Executive CRUK Clinical Cancer Centre
• Management Executive CRUK Cancer Trials Unit

D Onion, P Patel, RG Pineda, ND James, V Mautner (2009)'Antivector and Tumor Immune Responses Following Adenovirus-Directed Enzyme Prodrug Therapy for the Treatment of Prostate Cancer'. Human Gene Therapy 20 1249-1258

ND James, JS Pascoe, A Zachariah, D Ray, A Oldroyd, H Parry, H Benghiat, M Karina, SI Collins, E Porfiri (2009) 'Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors'. Clinical oncology (Royal College of Radiologists (Great Britain) 21 610-6

R T Bryan, MPA Zeegers, ND James, DM Wallace, KK Cheng (2009) 'Biomarkers in bladder cancer'. BJU international

MPA Zeegers, R T Bryan, C Langford, LJ Billingham, PG Murray, NS Deshmukh, SA Hussain, ND James, DM Wallace, KK Cheng (2009) 'The West Midlands Bladder Cancer Prognosis Programme: rationale and design'. BJU international

GS Cruickshank, D Ngoga, A Detta, S Green, ND James, C Wojnecki, JP Doran, J Hardie, M Chester, N Graham, Z Ghani, G Halbert, M Elliot, S Ford, R Braithwaite, TMT Sheehan, J Vickerman, N Lockyer, H Steinfeldt, G Croswell, A Chopra, R Sugar, A Boddy (2009) 'A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT'. Applied Radiation and Isotopes 67 S31-S33

P Patel, JG Young, V Mautner, D Ashdown, SL Bonney, RG Pineda, SI Collins, PF Searle, D Hull, E Peers, J Chester, DM Wallace, A Doherty, H Leung, LS Young, ND James (2009) 'APhase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984'. Molecular therapy : the journal of the American Society of Gene Therapy

J Ansari, A Fatima, S Chaudhri, RI Bhatt, DM Wallace, ND James (2009) 'Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney'. Onkologie 32 44-46

JG Young, NK Green, V Mautner, PF Searle, LS Young, ND James (2008) 'Combining gene and immunotherapy for prostate cancer'. Prostate Cancer and Prostatic Diseases 11 187-93

MD Mason, MR Sydes, J Glaholm, RE Langley, RA Huddart, M Sokal, M Stott, AC Robinson, ND James, MK Parmar, DP Dearnaley (2007) 'Oral sodium clodronate for non-metastatic prostate cancer - results of a randomized double-blind placebo-controlled trial: Medical Research Council PRO4 (ISRCTN61384873)'. Journal of the National Cancer Institute 99 765-776

SA Hussain, R Ganesan, GM Reynolds, L Gross, AJ Stevens, J Pastorek, PG Murray, B Perunovic, LJ Billingham, ND James, D Spooner, CJ Poole, DW Rea, D Palmer (2007) 'Hypoxia regulated Carbonic Anhydrase IX expression is associated with poor survival in patients with invasive breast cancer'. British Journal of Cancer 96 104-109

S Rathinam, SO Nyangoma, DG Ward, A Alzetani, J Starczynski, A Martin, P Johnson, ND James, PB Rajesh (2007) 'Proteomic analysis of resectable non-small cell lung cancer: Impact of smoking, histological type and stage of disease'. Thorax 62 A11-A12

SA Hussain, DW Rea, ND James, D Palmer (2007) 'Signal transduction therapy: Challenges to Clinical Trial Design'. Current Signal Transduction Therapy 2 21-30

R T Bryan, SA Hussain, DMA Wallace, ND James, JA Jankowski (2005) 'Molecular pathways in bladder cancer (I)'. BJU International 95 485-490

R T Bryan, SA Hussain, DMA Wallace, ND James, JA Jankowski (2005) 'Molecular pathways in bladder cancer (II)'. BJU International 95 491-496

SA Hussain, ND James (2005) 'Role of molecular markers in bladder cancer'. Seminars in Radiation Oncology 15 3-9

ND James, SA Hussain (2005) 'Management of muscle invasive bladder cancer - can we improve the results of bladder preserving therapy?' Seminars in Radiation Oncology 15 19-27

D Palmer, V Mautner, DF Mirza, S Oliff, W Gerritsen, JR van der Sijp, SG Hubscher, GM Reynolds, SL Bonney, R Rajaratnam, D Hull, M Horne, J Ellis, A Mountain, SC Hill, PA Harris, PF Searle, LS Young, ND James, DJ Kerr (2004) 'Virus directed enzyme prodrug therapy: Intratumoural administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer'. Journal of Clinical Oncology 22 1546-1552

SA Hussain, DD Stocken, DR Peake, J Glaholm, A Zarkar, DMA Wallace, ND James (2004) 'Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer'. British Journal of Cancer 90 2106-2111

SA Hussain, DD Stocken, P Riley, D Palmer, DR Peake, JI Geh, D Spooner, ND James (2004) 'A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer'. British Journal of Cancer 91 844-849

MJ Campbell, LM Gommersall, FL Khanim, DM Peehl, AP Doherty, ND James (2004) 'Co-repressor complexes as a novel chemoprevention target for prostate cancer'. British Prostate Group - Spring Meeting

D Palmer, SA Hussain, R Ganesan, PW Cooke, DM Wallace, LS Young, ND James (2004) 'CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule'. Oncology Reports 12 679-682

PF Searle, M Chen, L Hu, PR Race, A Lovering, JI Grove, C Guise, M Jaberipour, ND James, V Mautner, LS Young, DJ Kerr, A Mountain, SA White, EI Hyde (2004) 'Nitroreductase: A prodrug-activating enzyme for cancer gene therapy'. Clinical and Experimental Pharmacology and Physiology 31 811-816

SA Hussain, D Palmer, R Ganesan, L Hiller, J Gregory, PG Murray, J Pastorek, LS Young, ND James (2004) 'Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder'. Oncology Reports 11 1005-1010

LM Gommersall, E Marsden, A Doherty, DM Peehl, ND James, MJ Campbell (2004) 'Targeting SMRT co-repressor complexes as a novel chemoprevention strategy for prostate cancer'. British Association for Cancer Research Meeting (British Journal of Cancer) 91 Supp 1

D Wilson, L Hiller, L Gray, M Grainger, A Stirling, ND James (2003) 'The effect of biological effective dose on response and time to symptom progression in metastatic renal cell carcinoma'. Clinical Oncology 15 400-407

SA Hussain, ND James (2003) 'The systemic treatment of advanced and metastatic bladder cancer'. Lancet Oncology 4 489-497

SA Hussain, R Ganesan, L Hiller, PG Murray, MM El-Magraby, LS Young, ND James (2003) 'Pro-apoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder'. British Journal of Cancer 88 586-592

SA Hussain, R Ganesan, L Hiller, PW Cooke, PG Murray, LS Young, ND James (2003)'BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder'. Oncology Reports 10 571-576

SA Hussain, ND James (2002) 'Organ preservation strategies in bladder cancer'. Expert review of anticancer therapy 2 641-51

PF Searle, ID Spiers, J Simpson, ND James (2002) 'Cancer gene therapy: From science to clinical trials'. Drug Delivery Systems and Sciences 2 5-12

SA Hussain, DD Stocken, J Glaholm, DR Peake, DM Wallace, ND James (2001) 'A Phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer'. Annals of Oncology 12 929-935

SA Hussain, DR Ferry, G El-Gazzaz, DF Mirza, ND James, P McMaster, DJ Kerr (2001) 'Hepatocellular carcinoma'. Annals of Oncology 12 161-172

• French

Co-Director, Birmingham Clinical Research Academy

Nick has been interviewed regularly about his own work, particularly in the treatment of prostate cancer (BBC News Online). Nick has also been a regular commentator on the availability of cancer drugs on the NHS.

• Dr Pamela Kearns
• Professor Paul Moss